KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Inventory: 2012-2024

Historic Inventory for Regeneron Pharmaceuticals (REGN) over the last 13 years, with Dec 2024 value amounting to $3.1 billion.

  • Regeneron Pharmaceuticals' Inventory rose 7.83% to $3.3 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $3.3 billion, marking a year-over-year increase of 7.83%. This contributed to the annual value of $3.1 billion for FY2024, which is 19.64% up from last year.
  • According to the latest figures from FY2024, Regeneron Pharmaceuticals' Inventory is $3.1 billion, which was up 19.64% from $2.6 billion recorded in FY2023.
  • Over the past 5 years, Regeneron Pharmaceuticals' Inventory peaked at $3.1 billion during FY2024, and registered a low of $1.9 billion during FY2020.
  • Over the past 3 years, Regeneron Pharmaceuticals' median Inventory value was $2.6 billion (recorded in 2023), while the average stood at $2.7 billion.
  • Data for Regeneron Pharmaceuticals' Inventory shows a peak YoY surged of 35.40% (in 2020) over the last 5 years.
  • Yearly analysis of 5 years shows Regeneron Pharmaceuticals' Inventory stood at $1.9 billion in 2020, then increased by 1.81% to $2.0 billion in 2021, then climbed by 23.09% to $2.4 billion in 2022, then climbed by 7.44% to $2.6 billion in 2023, then climbed by 19.64% to $3.1 billion in 2024.